维生素D作为呼吸窘迫综合征危险因素的最新进展。

Q1 Pharmacology, Toxicology and Pharmaceutics
Advances in Pharmacological Sciences Pub Date : 2018-09-30 eCollection Date: 2018-01-01 DOI:10.1155/2018/8494816
Vesara Ardhe Gatera, Rizky Abdulah, Ida Musfiroh, Raden Tina Dewi Judistiani, Budi Setiabudiawan
{"title":"维生素D作为呼吸窘迫综合征危险因素的最新进展。","authors":"Vesara Ardhe Gatera,&nbsp;Rizky Abdulah,&nbsp;Ida Musfiroh,&nbsp;Raden Tina Dewi Judistiani,&nbsp;Budi Setiabudiawan","doi":"10.1155/2018/8494816","DOIUrl":null,"url":null,"abstract":"<p><p>To update the guidelines regarding vitamin D status in respiratory distress syndrome, we reviewed recent human and animal studies on the benefits of vitamin D in respiratory distress. We searched PubMed and ProQuest for studies on the use of vitamin D from 2009 to 2017. The common parameters in these studies included the use of lung tissue, phospholipids, blood, and plasma to assess the effects of vitamin D on respiratory syndrome. The metabolized form of vitamin D used in these studies was 1,25(OH)<sub>2</sub>D<sub>3</sub> in animal studies and 25(OH)D in human studies. Vitamin D supplementation decreases the risk of respiratory distress syndrome, improves the quality of life, and is relatively effective and safe for preterm neonates as well as during lung maturation. However, although vitamin D supplementation may offer benefits for respiratory distress syndrome, the optimal dosing strategies for specific types of risk factors in the lungs must be clarified to confirm the therapeutic efficacy.</p>","PeriodicalId":7389,"journal":{"name":"Advances in Pharmacological Sciences","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/8494816","citationCount":"17","resultStr":"{\"title\":\"Updates on the Status of Vitamin D as a Risk Factor for Respiratory Distress Syndrome.\",\"authors\":\"Vesara Ardhe Gatera,&nbsp;Rizky Abdulah,&nbsp;Ida Musfiroh,&nbsp;Raden Tina Dewi Judistiani,&nbsp;Budi Setiabudiawan\",\"doi\":\"10.1155/2018/8494816\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>To update the guidelines regarding vitamin D status in respiratory distress syndrome, we reviewed recent human and animal studies on the benefits of vitamin D in respiratory distress. We searched PubMed and ProQuest for studies on the use of vitamin D from 2009 to 2017. The common parameters in these studies included the use of lung tissue, phospholipids, blood, and plasma to assess the effects of vitamin D on respiratory syndrome. The metabolized form of vitamin D used in these studies was 1,25(OH)<sub>2</sub>D<sub>3</sub> in animal studies and 25(OH)D in human studies. Vitamin D supplementation decreases the risk of respiratory distress syndrome, improves the quality of life, and is relatively effective and safe for preterm neonates as well as during lung maturation. However, although vitamin D supplementation may offer benefits for respiratory distress syndrome, the optimal dosing strategies for specific types of risk factors in the lungs must be clarified to confirm the therapeutic efficacy.</p>\",\"PeriodicalId\":7389,\"journal\":{\"name\":\"Advances in Pharmacological Sciences\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1155/2018/8494816\",\"citationCount\":\"17\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Pharmacological Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2018/8494816\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2018/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Pharmacological Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2018/8494816","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 17

摘要

为了更新关于呼吸窘迫综合征中维生素D状态的指南,我们回顾了最近关于维生素D在呼吸窘迫中的益处的人类和动物研究。我们检索了PubMed和ProQuest关于2009年至2017年维生素D使用的研究。这些研究中的常用参数包括使用肺组织、磷脂、血液和血浆来评估维生素D对呼吸综合征的影响。这些研究中使用的维生素D的代谢形式是动物研究中的1,25(OH)2D3和人类研究中的25(OH)D。补充维生素D可降低呼吸窘迫综合征的风险,提高生活质量,对早产儿和肺成熟期间相对有效和安全。然而,尽管补充维生素D可能对呼吸窘迫综合征有益,但必须明确针对肺部特定类型风险因素的最佳剂量策略,以确认治疗效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Updates on the Status of Vitamin D as a Risk Factor for Respiratory Distress Syndrome.

Updates on the Status of Vitamin D as a Risk Factor for Respiratory Distress Syndrome.

To update the guidelines regarding vitamin D status in respiratory distress syndrome, we reviewed recent human and animal studies on the benefits of vitamin D in respiratory distress. We searched PubMed and ProQuest for studies on the use of vitamin D from 2009 to 2017. The common parameters in these studies included the use of lung tissue, phospholipids, blood, and plasma to assess the effects of vitamin D on respiratory syndrome. The metabolized form of vitamin D used in these studies was 1,25(OH)2D3 in animal studies and 25(OH)D in human studies. Vitamin D supplementation decreases the risk of respiratory distress syndrome, improves the quality of life, and is relatively effective and safe for preterm neonates as well as during lung maturation. However, although vitamin D supplementation may offer benefits for respiratory distress syndrome, the optimal dosing strategies for specific types of risk factors in the lungs must be clarified to confirm the therapeutic efficacy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Advances in Pharmacological Sciences
Advances in Pharmacological Sciences PHARMACOLOGY & PHARMACY-
CiteScore
6.40
自引率
0.00%
发文量
0
审稿时长
14 weeks
期刊介绍: Advances in Pharmacological and Pharmaceutical Sciences is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies in all areas of experimental and clinical pharmacology, pharmaceutics, medicinal chemistry and drug delivery. Topics covered by the journal include, but are not limited to: -Biochemical pharmacology, drug mechanism of action, pharmacodynamics, pharmacogenetics, pharmacokinetics, and toxicology. -The design and preparation of new drugs, and their safety and efficacy in humans, including descriptions of drug dosage forms. -All areas of medicinal chemistry, such as drug discovery, design and synthesis. -Basic biology of drug and gene delivery through to application and development of these principles, through therapeutic delivery and targeting. Areas covered include bioavailability, controlled release, microcapsules, novel drug delivery systems, personalized drug delivery, and techniques for passing biological barriers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信